301 related articles for article (PubMed ID: 7796869)
61. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
Suzuki T; Izumimoto N; Takezawa Y; Fujimura M; Togashi Y; Nagase H; Tanaka T; Endoh T
Brain Res; 2004 Jan; 995(2):167-75. PubMed ID: 14672806
[TBL] [Abstract][Full Text] [Related]
62. Roles of central and peripheral mu, delta and kappa opioid receptors in the mediation of gastric acid secretory effects in the rat.
Fox DA; Burks TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):456-62. PubMed ID: 2831341
[TBL] [Abstract][Full Text] [Related]
63. Immunomodulatory activity of mu- and kappa-selective opioid agonists.
Taub DD; Eisenstein TK; Geller EB; Adler MW; Rogers TJ
Proc Natl Acad Sci U S A; 1991 Jan; 88(2):360-4. PubMed ID: 1846441
[TBL] [Abstract][Full Text] [Related]
64. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U-50,488H against noxious thermal, mechanical and inflammatory stimuli.
Idänpään-Heikkilä JJ; Kalso EA; Seppälä T
J Pharmacol Exp Ther; 1994 Dec; 271(3):1306-13. PubMed ID: 7996439
[TBL] [Abstract][Full Text] [Related]
65. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes.
Rothman RB; France CP; Bykov V; De Costa BR; Jacobson AE; Woods JH; Rice KC
Eur J Pharmacol; 1989 Aug; 167(3):345-53. PubMed ID: 2553442
[TBL] [Abstract][Full Text] [Related]
66. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit.
Feng P; Rahim RT; Cowan A; Liu-Chen LY; Peng X; Gaughan J; Meissler JJ; Adler MW; Eisenstein TK
Eur J Pharmacol; 2006 Mar; 534(1-3):250-7. PubMed ID: 16513108
[TBL] [Abstract][Full Text] [Related]
67. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse.
Yajima Y; Narita M; Takahashi-Nakano Y; Misawa M; Nagase H; Mizoguchi H; Tseng LF; Suzuki T
Brain Res; 2000 Apr; 862(1-2):120-6. PubMed ID: 10799676
[TBL] [Abstract][Full Text] [Related]
68. Pre- and post-synaptic effects of spiradoline and U-50488H, selective kappa opioid receptor agonists, in isolated ileum.
Nomura Y; Hayashi S
Scand J Gastroenterol; 1992 Apr; 27(4):295-302. PubMed ID: 1317055
[TBL] [Abstract][Full Text] [Related]
69. Hyperglycemia does not modify the pupillary effects of mu and kappa opiate agonists in mice.
Bansinath M; Ramabadran K; Turndorf H; Puig MM
J Ocul Pharmacol; 1989; 5(1):33-43. PubMed ID: 2541211
[TBL] [Abstract][Full Text] [Related]
70. Modulation of opioid analgesia by agmatine.
Kolesnikov Y; Jain S; Pasternak GW
Eur J Pharmacol; 1996 Jan; 296(1):17-22. PubMed ID: 8720472
[TBL] [Abstract][Full Text] [Related]
71. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
72. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
Milanés MV; Vargas ML; Martín MI
Eur J Pharmacol; 1994 Dec; 271(1):103-9. PubMed ID: 7698193
[TBL] [Abstract][Full Text] [Related]
73. Beneficial effects of the kappa opioid receptor agonist U-50488H in experimental acute brain and spinal cord injury.
Hall ED; Wolf DL; Althaus JS; Von Voigtlander PF
Brain Res; 1987 Dec; 435(1-2):174-80. PubMed ID: 2827851
[TBL] [Abstract][Full Text] [Related]
74. Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin.
Suh HW; Sim YB; Choi YS; Song DK; Kim YH
Gen Pharmacol; 1995 Nov; 26(7):1597-602. PubMed ID: 8690252
[TBL] [Abstract][Full Text] [Related]
75. Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats.
Diop L; Rivière PJ; Pascaud X; Dassaud M; Junien JL
Eur J Pharmacol; 1994 May; 257(1-2):181-7. PubMed ID: 8082700
[TBL] [Abstract][Full Text] [Related]
76. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
77. Differential effects of K+ channel blockers on antinociception induced by alpha 2-adrenoceptor, GABAB and kappa-opioid receptor agonists.
Ocaña M; Baeyens JM
Br J Pharmacol; 1993 Nov; 110(3):1049-54. PubMed ID: 7905339
[TBL] [Abstract][Full Text] [Related]
78. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
79. Repeated acquisition of behavioral chains in squirrel monkeys: comparisons of a mu, kappa and delta opioid agonist.
Pakarinen ED; Woods JH; Moerschbaecher JM
J Pharmacol Exp Ther; 1995 Feb; 272(2):552-9. PubMed ID: 7853168
[TBL] [Abstract][Full Text] [Related]
80. Nonopioid actions of the kappa-opioid receptor agonists, U 50488H and U 69593 on electrophysiologic properties of hippocampal CA3 neurons in vitro.
Alzheimer C; ten Bruggencate G
J Pharmacol Exp Ther; 1990 Nov; 255(2):900-5. PubMed ID: 1978733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
